Shree Ganesh Remedies Ltd
Shree Ganesh Remedies is engaged in chemical
manufacturing, specialising in pharmaceutical
intermediates and speciality chemicals.[1]
- Market Cap ₹ 948 Cr.
- Current Price ₹ 738
- High / Low ₹ 950 / 558
- Stock P/E 32.6
- Book Value ₹ 104
- Dividend Yield 0.00 %
- ROCE %
- ROE %
- Face Value ₹ 10.0
Pros
- Company has delivered good profit growth of 35.1% CAGR over last 5 years
Cons
- Stock is trading at 7.12 times its book value
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2024 | TTM | |
|---|---|---|---|---|---|
| 35 | 64 | 49 | 126 | 121 | |
| 26 | 52 | 35 | 84 | 75 | |
| Operating Profit | 9 | 13 | 14 | 42 | 46 |
| OPM % | 25% | 20% | 28% | 33% | 38% |
| 1 | 4 | 2 | 3 | 3 | |
| Interest | 0 | 1 | 0 | 1 | 1 |
| Depreciation | 1 | 2 | 3 | 6 | 9 |
| Profit before tax | 9 | 14 | 13 | 38 | 39 |
| Tax % | 28% | 23% | 25% | 26% | |
| 6 | 10 | 10 | 28 | 29 | |
| EPS in Rs | 4.88 | 8.18 | 7.62 | 21.96 | 22.66 |
| Dividend Payout % | 18% | 13% | 18% | 2% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 29% |
| 3 Years: | 37% |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 35% |
| 3 Years: | 42% |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 69% |
| 3 Years: | 32% |
| 1 Year: | 20% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2024 | Sep 2024 | |
|---|---|---|---|---|
| Equity Capital | 9 | 9 | 13 | 13 |
| Reserves | 25 | 33 | 109 | 120 |
| 1 | 4 | 36 | 34 | |
| 7 | 9 | 12 | 11 | |
| Total Liabilities | 41 | 55 | 171 | 178 |
| 14 | 20 | 81 | 97 | |
| CWIP | 0 | 0 | 17 | 3 |
| Investments | 4 | 3 | 5 | 7 |
| 23 | 32 | 69 | 72 | |
| Total Assets | 41 | 55 | 171 | 178 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2024 | |
|---|---|---|---|---|
| -5 | 5 | 3 | 30 | |
| -0 | -3 | -1 | -33 | |
| -0 | -0 | -1 | 10 | |
| Net Cash Flow | -5 | 1 | 2 | 7 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2024 | |
|---|---|---|---|---|
| Debtor Days | 101 | 101 | 59 | |
| Inventory Days | 125 | 61 | 156 | |
| Days Payable | 75 | 43 | 51 | |
| Cash Conversion Cycle | 151 | 119 | 164 | |
| Working Capital Days | 149 | 115 | 110 | |
| ROCE % | 35% |
Documents
Announcements
-
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
26 Apr - Company confirms it does not qualify as Large Corporate under SEBI criteria for FY ending March 2025.
-
Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
26 Apr - Shree Ganesh Remedies confirms non-applicability as Large Corporate per SEBI for FY 2024-25.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
7 Apr - Submission of confirmation certificate under SEBI regulations.
- Closure of Trading Window 25 Mar
-
Commissioning Of 2.5 MW Solar Power Project
25 Mar - Commissioning of 2.5 MW Solar Power Project.
Evolution of Business[1]
The company is changing its focus from Intermediates for Off-patent and generic drugs towards patented molecules requiring strong technical know how. The revenue contribution from Intermediates has also shifted from 90% to <60%.